

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 September 2009 (03.09.2009)

PCT

(10) International Publication Number
WO 2009/108390 A3

(51) International Patent Classification:
A61K 38/18 (2006.01) A61P 25/02 (2006.01)

(74) Agents: Landrum, Charles, P. et al.; Fulbright & Jaworski L.L.P., 600 Congress Ave., Suite 2400, Austin, TX 78701 (US).

(21) International Application Number:
PCT/US2009/001356

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(22) International Filing Date:
2 March 2009 (02.03.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/067,589 29 February 2008 (29.02.2008) US

(71) Applicant (for all designated States except US): ACORDA THERAPEUTICS, INC. [US/US]; 15 Skyline Drive, Hawthorne, NY 10532 (US).


(72) Inventors; and
(75) Inventors/Applicants (for US only): KIM, Haesun [US/US]; c/o Rutgers University, College Avenue, New Brunswick, NJ 08901 (US). CAGGIANO, Anthony, O. [US/US]; c/o Acorda Therapeutics, Inc., 15 Skyline Drive, Hawthorne, NY 10532 (US).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR),

[Continued on next page]

(54) Title: METHOD FOR ACHIEVING DESIRED GLIAL GROWTH FACTOR 2 PLASMA LEVELS

Figure 1



(57) Abstract: The present invention relates to administering glial growth factor 2 (GGF2) to a patient in need thereof, to achieve serum levels of GGF2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient. In a particular embodiment, the patient is suffering from a disease or disorder associated with reduced levels of myelination and the GGF2 is administered to promote myelination in the patient.

WO 2009/108390 A3



OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). (88) Date of publication of the international search report:
18 November 2010

Published:

— *with international search report (Art. 21(3))*

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2009/001356

A. CLASSIFICATION OF SUBJECT MATTER
 INV. A61K38/18 A61P25/02
 ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, BIOSIS, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2004/110359 A2 (ACORDA THERAPEUTICS INC [US]; GRUSKIN ELLIOTT A [US]; CAGGIANO ANTHONY) 23 December 2004 (2004-12-23)	1-4, 11, 17, 18
Y	paragraphs [0054], [0072]; claims; example 2	1-28
Y	WO 94/04560 A1 (LUDWIG INST CANCER RES [GB]; GOODEARL ANDREW DAVID JOHN [GB]; STROOBAN) 3 March 1994 (1994-03-03) claims	1-28
	----- -/--	

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents :

<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>
--	--

Date of the actual completion of the international search 5 August 2010	Date of mailing of the international search report 18/08/2010
---	---

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Langer, Astrid
--	---

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2009/001356

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	OGATA TORU ET AL: "Opposing extracellular signal-regulated kinase and Akt pathways control Schwann cell myelination" JOURNAL OF NEUROSCIENCE, vol. 24, no. 30, 28 July 2004 (2004-07-28) , pages 6724-6732, 6703, XP002595402 ISSN: 0270-6474	1-27
Y	Abstract; * abstract; figures	1-28
X	MAUREL PATRICE ET AL: "Axonal regulation of Schwann cell proliferation and survival and the initial events of myelination requires PI 3-kinase activity" JOURNAL OF NEUROSCIENCE, vol. 20, no. 12, 15 June 2000 (2000-06-15) , pages 4635-4645, XP002595403 ISSN: 0270-6474	27
Y	Abstract; page 4636, column 2, paragraph 4	1-28
T	SYED NEERAJA ET AL: "Soluble Neuregulin-1 Has Bifunctional, Concentration-Dependent Effects on Schwann Cell Myelination" JOURNAL OF NEUROSCIENCE, vol. 30, no. 17, April 2010 (2010-04), pages 6122-6131, XP09137128 ISSN: 0270-6474 the whole document	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2009/001356

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2004110359 A2	23-12-2004	AU 2004247025 A1	23-12-2004
		CA 2525782 A1	23-12-2004
		EP 1646353 A2	19-04-2006
		JP 2007516229 T	21-06-2007
		MX PA05012306 A	18-04-2006
WO 9404560 A1	03-03-1994	AU 4725793 A	15-03-1994
		PT 101337 A	29-07-1994
		ZA 9305908 A	09-03-1994